Trial Profile

Phase 1b Study of Andecaliximab in Participants With Spinal Cord Injury at Risk of Developing Heterotopic Ossification

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 09 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Andecaliximab (Primary)
Indications Fibrodysplasia ossificans progressiva; Heterotopic ossification
Focus Adverse reactions; Pharmacokinetics
Acronyms ANDECA-HO
Sponsors ashibio

Most Recent Events

24 Jun 2025 According to an ashibio media release, first patient has been dosed in this study. Andrew Park, MD, Physician Scientist at Craig Hospital in Englewood, Colo., who dosed the first patient in the SCI study is the Principal Investigator of this trial. This study will support a future randomized trial in patients with HO related to SCI and other conditions.
23 Jun 2025 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com